<SEC-DOCUMENT>0000078003-17-000027.txt : 20170526
<SEC-HEADER>0000078003-17-000027.hdr.sgml : 20170526
<ACCEPTANCE-DATETIME>20170526124043
ACCESSION NUMBER:		0000078003-17-000027
CONFORMED SUBMISSION TYPE:	SC 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20170526
DATE AS OF CHANGE:		20170526

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			pSivida Corp.
		CENTRAL INDEX KEY:			0001314102
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				262774444
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		SC 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-81613
		FILM NUMBER:		17872921

	BUSINESS ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-926-5000

	MAIL ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida LTD
		DATE OF NAME CHANGE:	20050111

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		2125732323

	MAIL ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D/A
<SEQUENCE>1
<FILENAME>pf13da2ps.htm
<DESCRIPTION>SCHEDULE 13D AMENDMENT NO. 2
<TEXT>
<html>
<head>
<title>Schedule 13DA</title>
</head>

<body bgcolor="#FFFFFF" text="#000000">
<p align="center"> <br>
  <b>UNITED STATES <br>
  SECURITIES AND EXCHANGE COMMISSION <br>
  Washington, D.C. 20549</b><br>
  <br>
  <b>SCHEDULE 13D<br>
  Under the Securities Exchange Act of 1934<br>
  (Amendment No. 2)*</b><br>
  <br>
  <strong>PSIVIDA CORP.</strong><br>
  (Name of Issuer)</p>
<p align="center"><strong>Common Stock, par value $0.001 per share</strong><br>
  (Title of Class of Securities)</p>
<p align="center"><strong>74440J101</strong><br>
  (CUSIP Number)</p>
<p align="center"><strong>Margaret M. Madden, Esq.</strong><strong> </strong><br>
  <strong>Vice  President and Corporate Secretary, </strong><br>
  <strong>Chief  Governance Counsel<br>
  Pfizer Inc.<br>
    235 East 42nd Street<br>
    New York, New York 10017<br>
(212) 733-2323</strong></p>
<p align="center">(Name, Address and Telephone Number of Person <br>
  Authorized to Receive Notices and Communications)</p>
<p align="center"><strong>May 15, 2017</strong></p>
<p align="center">(Date of Event which Requires Filing of this Statement)</p>
<p align="left">&nbsp;</p>
<p>If the filing person has previously filed  a statement on Schedule 13G to report the acquisition that is the subject of  this Schedule 13D, and is filing this schedule because of &sect;&sect; 240.13d-1(e),  240.13d-1(f) or 240.13d-1(g), check the following box. |_|<br>
  &nbsp; <br>
  <strong>Note:</strong>&nbsp; Schedules filed in  paper format shall include a signed original and five copies of the schedule,  including all exhibits.&nbsp; See &sect; 240.13d-7  for other parties to whom copies are to be sent. <br>
  &nbsp; <br>
  *The remainder of this cover page shall be  filled out for a reporting person's initial filing on this form with respect to  the subject class of securities, and for any subsequent amendment containing  information which would alter the disclosures provided in a prior cover page.  &nbsp; </p>
The information required on the remainder of this  cover page shall not be deemed to be
&quot;filed&quot; for the purpose of Section 18 of  the Securities Exchange Act of 1934 (&quot;Act&quot;) or otherwise subject to the  liabilities of that section of the Act but shall be subject to all other  provisions of the Act (however, see the Notes).
<p align="left">&nbsp;</p>
CUSIP No.  <strong>74440J101</strong>&nbsp; <br>
<br>
1. Names of Reporting Persons IRS Identification Nos. of above persons (entities
only)<br>
Pfizer Inc. &nbsp;13-5315170<br>
<br>
2. Check the Appropriate Box if a Member of a Group (See Instructions)<br>
<br>
(a) <br>
<br>
(b) <br>
<br>
3. SEC Use Only ........................................................................................
<br>
<br>
4. Source of Funds (See Instructions) &nbsp;&nbsp;WC<br>
<br>
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d)
or 2(e) <br>
<br>
6. Citizenship or Place of Organization Delaware
<p>&nbsp;</p>
<table width="83%" border="0">
  <tr>
    <td rowspan="4" width="24%">
      <div align="center">
        <p align="left">NUMBER OF<br>
          <br>
          SHARES<br>
          <br>
          BENEFICIALLY </p>
        <p align="left">OWNED BY EACH REPORTING</p>
        <p align="left"> PERSON WITH<br>
        </p>
      </div>
    </td>
    <td width="63%" height="47">7. Sole Voting Power &nbsp;&nbsp;&nbsp;1,862,093</td>
  </tr>
  <tr>
    <td width="63%" height="43">8. Shared Voting Power &nbsp;&nbsp;0</td>
  </tr>
  <tr>
    <td width="63%" height="53">9. Sole Dispositive Power 1,862,093</td>
  </tr>
  <tr>
    <td width="63%" height="60">10. Shared Dispositive Power &nbsp;&nbsp;0</td>
  </tr>
</table>
<p>11. Aggregate Amount Beneficially Owned by Each Reporting Person&nbsp;&nbsp;1,862,093<br>
  <br>
  12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |_|<br>
  <br>
  13. Percent of Class Represented by Amount in Row (11) &nbsp;&nbsp;4.7%<br>
  <br>
14. Type of Reporting Person (See Instructions) CO</p>
<p>This Amendment No. 2 (this &quot;Amendment No. 2&quot;) amends  and supplements the statement on Schedule 13D originally filed by Pfizer Inc. (&quot;Pfizer&quot;)  with the U.S. Securities and Exchange Commission on July 16, 2007 (the
&quot;Original Schedule  13D&quot;), as amended by Amendment No. 1 to the Schedule 13D,
filed on May 1, 2015 (&quot;Amendment No. 1&quot;) and, with the Original Schedule 13D, the
&quot;Schedule 13D&quot;) and relates to the common stock, par value $0.001 per share (&quot;Common  Stock&quot;), of pSivida Corp. (the
&quot;Issuer&quot;). This Amendment No. 2&nbsp; is being filed to disclose that Pfizer
ceased to be a beneficial owner of more than five percent of the outstanding
shares of Common Stock of the Issuer as a result of dilution due to equity
issuances by the Issuer. &nbsp;Except as specifically provided herein, this  Amendment
No. 2&nbsp; does not modify any of the information previously reported on the  Schedule 13D.&nbsp; Unless otherwise  indicated, each capitalized term used but not defined herein shall have the meaning  assigned to such term in the Schedule 13D. <strong></strong></p>
<p><strong>Item 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest in Securities of the Issuer<br>
  </strong><br>
  Item 5 is  hereby amended and supplemented as follows:</p>
<p><strong>(a) </strong>The  information set forth on the cover pages to this Amendment
No. 2 is incorporated  herein by reference. </p>
<p><strong>(b) </strong>The  information set forth on the cover pages to this Amendment
No. 2 is incorporated  herein by reference. <br>
  <br>
  <strong>(c) </strong>Pfizer  has not engaged in any transactions with respect to the Issuer's Common Stock  in the past 60 days.<br>
  <br>
  <strong>(d) </strong>Not applicable.<br>
  <br>
  <strong>(e) </strong>As a result primarily of offerings of Common Stock by the
Issuer pursuant to an underwritten public offering in January 2016 and an
at-the-market equity offering program between March 1, 2017 and May 9, 2017,
Pfizer's ownership in the Issuer as reported on the Schedule 13D has been
diluted. As a result of this dilution, Pfizer has ceased to be the beneficial
owner of more than five percent of the Issuer's Common Stock.&nbsp;</p>
<p>The ownership percentage set forth in Row 13 of the  cover page hereto has been calculated based on an assumed total of
39,356,999  shares of Common Stock outstanding as of&nbsp; May 10, 2017, as reported in the Issuer&rsquo;s
Proxy Statement on Form 14A filed with SEC on May 15, 2017.</p>
<p>&nbsp;</p>
<p align="center"><br>
  <i><b>Signature</b></i></p>
<p>After reasonable inquiry and to the best of my knowledge and  belief, I certify that the information set forth in this statement is true,  complete and correct.<br>
  &nbsp;</p>
<p align="left">  Dated: May 26, 2017</p>
<p align="left">Pfizer Inc. </p>
<p>By: <u>/s/ Susan Grant</u><br>
  Name: Susan Grant
  <br>
  Title:&nbsp;Assistant Secretary <br>
</p>
<p align="center">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
